MX2011005054A - Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple. - Google Patents
Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple.Info
- Publication number
- MX2011005054A MX2011005054A MX2011005054A MX2011005054A MX2011005054A MX 2011005054 A MX2011005054 A MX 2011005054A MX 2011005054 A MX2011005054 A MX 2011005054A MX 2011005054 A MX2011005054 A MX 2011005054A MX 2011005054 A MX2011005054 A MX 2011005054A
- Authority
- MX
- Mexico
- Prior art keywords
- bendamustine
- doxorubicin
- multiple myeloma
- bortezomib
- treatment
- Prior art date
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title abstract 4
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002707 bendamustine Drugs 0.000 title abstract 2
- 229960004679 doxorubicin Drugs 0.000 title abstract 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 title 1
- 229960001467 bortezomib Drugs 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11428408P | 2008-11-13 | 2008-11-13 | |
| PCT/US2009/064009 WO2010056733A1 (en) | 2008-11-13 | 2009-11-11 | Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011005054A true MX2011005054A (es) | 2011-09-06 |
Family
ID=42170295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011005054A MX2011005054A (es) | 2008-11-13 | 2009-11-11 | Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110217258A1 (https=) |
| EP (1) | EP2350665A4 (https=) |
| JP (1) | JP2012508749A (https=) |
| CA (1) | CA2741276A1 (https=) |
| MX (1) | MX2011005054A (https=) |
| WO (1) | WO2010056733A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9918968B2 (en) | 2013-01-03 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | Rapamycin analogs targeting proteasome function in the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7815921B2 (en) * | 2002-03-22 | 2010-10-19 | Ludwid Maximilians Universitat | Cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy |
| ES2421516T3 (es) * | 2002-11-06 | 2013-09-03 | Dana Farber Cancer Inst Inc | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 |
| WO2006069073A2 (en) * | 2004-12-20 | 2006-06-29 | The General Hospital Corporation | Use of angiopoietins in anti-tumor therapy |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
-
2009
- 2009-11-11 WO PCT/US2009/064009 patent/WO2010056733A1/en not_active Ceased
- 2009-11-11 MX MX2011005054A patent/MX2011005054A/es not_active Application Discontinuation
- 2009-11-11 CA CA2741276A patent/CA2741276A1/en not_active Abandoned
- 2009-11-11 JP JP2011536438A patent/JP2012508749A/ja active Pending
- 2009-11-11 EP EP09826660A patent/EP2350665A4/en not_active Withdrawn
-
2011
- 2011-04-28 US US13/096,300 patent/US20110217258A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2350665A1 (en) | 2011-08-03 |
| WO2010056733A1 (en) | 2010-05-20 |
| CA2741276A1 (en) | 2010-05-20 |
| EP2350665A4 (en) | 2012-06-06 |
| JP2012508749A (ja) | 2012-04-12 |
| US20110217258A1 (en) | 2011-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| MX351892B (es) | Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso. | |
| WO2012103059A3 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| UA106748C2 (uk) | Похідні проліну як інгібітори катепсину | |
| EP3466423A3 (en) | Treatment of cancer with tor kinase inhibitors | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| NZ601350A (en) | Method of treating arthritis | |
| MX343968B (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
| MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
| MX2013007055A (es) | Derivados de sanglifehrina y metodos para su produccion. | |
| TN2011000214A1 (en) | Combination of hsp90 and herceptin inhibitors | |
| MX2011005054A (es) | Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple. | |
| TW200833343A (en) | Novel therapeutic utilization for the treatment of leukaemias | |
| MX2009010757A (es) | Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor. | |
| SG10201407435WA (en) | Methods and compositions for treating leukemia | |
| UA39503U (ru) | Способ комплексного лечения гиперчувствительности зубов | |
| HK1160221A (en) | Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma | |
| WO2010054381A3 (en) | Method of treating cancer with a combination of a proteasome inhibitor and salubrinal | |
| HK1192465A (en) | Proteasome inhibitor delanzomib for use in the treatment of lupus | |
| UA43082U (ru) | Способ лечения внутримозгового кровоизлияния | |
| UA29548U (en) | Method for treating osteoarthrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |